Core Binding Factor Acute Myelogenous Leukemia-2021 Treatment Algorithm

Overview

Journal Blood Cancer J

Date 2021 Jun 17

PMID 34135311

Citations 33

Authors

Gautam Borthakur

Hagop Kantarjian

Affiliations

Soon will be listed here.

Abstract

Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective implementation of available therapeutic measures and appropriate disease monitoring. The incorporation of gemtuzumab ozogamicin into frontline therapy should be standard. Cytarabine based induction/consolidation regimen may be combined with anthracycline (3 + 7 standard) or antimetabolite, fludarabine. Serial quantitative polymerase chain reaction (QPCR) monitoring of unique fusion transcripts allows monitoring for measurable residual disease clearance; this allows for better prognostication and well as treatment modifications.

Citing Articles

Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients.

Shen J, Shan M, Chu M, Cai Y, Rui J, Chen S Blood Cancer J. 2025; 15(1):17.

PMID: 39934109 PMC: 11814316. DOI: 10.1038/s41408-025-01227-7.

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.

Zheng S, Tong Y, Yang L, Chen J, Tan Y Ann Hematol. 2024; 103(12):5019-5033.

PMID: 39467855 DOI: 10.1007/s00277-024-06050-x.

Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.

Ngo D, Blackmon A, Al Malki M Bone Marrow Transplant. 2024; 60(1):83-85.

PMID: 39379697 DOI: 10.1038/s41409-024-02425-w.

Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia.

Mei Y, Liu Y, Liu W, Chen M, Liu X, Wang S Exp Hematol Oncol. 2024; 13(1):92.

PMID: 39243082 PMC: 11380426. DOI: 10.1186/s40164-024-00560-0.

Mutational cooperativity of RUNX1::RUNX1T1 isoform 9a and oncogenic NRAS in zebrafish myeloid leukaemia.

Lints R, Walker C, Delfi O, Prouse M, PohLui De Silva M, Bohlander S Biol Open. 2024; 13(9).

PMID: 39177514 PMC: 11381922. DOI: 10.1242/bio.060523.

References

Pollard J, Alonzo T, Gerbing R, Ho P, Zeng R, Ravindranath Y . Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010; 115(12):2372-9. PMC: 2845895. DOI: 10.1182/blood-2009-09-241075. View

Marcucci G, Caligiuri M, Dohner H, Archer K, Schlenk R, Dohner K . Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia. 2001; 15(7):1072-80. DOI: 10.1038/sj.leu.2402159. View

Borthakur G, Cortes J, Estey E, Jabbour E, Faderl S, OBrien S . Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014; 89(10):964-8. PMC: 4431614. DOI: 10.1002/ajh.23795. View

Paschka P, Marcucci G, Ruppert A, Mrozek K, Chen H, Kittles R . Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006; 24(24):3904-11. DOI: 10.1200/JCO.2006.06.9500. View

Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F . Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia. 2018; 32(12):2698-2701. DOI: 10.1038/s41375-018-0158-1. View

Schlenk R, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G . Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004; 22(18):3741-50. DOI: 10.1200/JCO.2004.03.012. View

Khan M, Cortes J, Qiao W, Alzubaidi M, Pierce S, Ravandi F . Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017; 18(1):e19-e25. PMC: 5861376. DOI: 10.1016/j.clml.2017.09.017. View

Allen C, Hills R, Lamb K, Evans C, Tinsley S, Sellar R . The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013; 27(9):1891-901. DOI: 10.1038/leu.2013.186. View

Hospital M, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T . Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood. 2014; 124(8):1312-9. DOI: 10.1182/blood-2014-01-549212. View

10.

Byrd J, Mrozek K, Dodge R, Carroll A, Edwards C, Arthur D . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100(13):4325-36. DOI: 10.1182/blood-2002-03-0772. View

11.

Kwong Y, Chan V, Wong K, Chan T . Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer. 1995; 75(3):821-5. DOI: 10.1002/1097-0142(19950201)75:3<821::aid-cncr2820750312>3.0.co;2-z. View

12.

Tobal K, Johnson P, Saunders M, Harrison C, Liu Yin J . Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol. 1995; 91(1):104-8. DOI: 10.1111/j.1365-2141.1995.tb05253.x. View

13.

Borthakur G, Lin E, Jain N, Estey E, Cortes J, OBrien S . Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009; 115(14):3217-21. PMC: 4184418. DOI: 10.1002/cncr.24367. View

14.

Paschka P, Schlenk R, Weber D, Benner A, Bullinger L, Heuser M . Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia. 2018; 32(7):1621-1630. DOI: 10.1038/s41375-018-0129-6. View

15.

Borthakur G, Kantarjian H, Wang X, Plunkett Jr W, Gandhi V, Faderl S . Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008; 113(11):3181-5. PMC: 4126078. DOI: 10.1002/cncr.23927. View

16.

Marcucci G, Mrozek K, Ruppert A, Maharry K, Kolitz J, Moore J . Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005; 23(24):5705-17. DOI: 10.1200/JCO.2005.15.610. View

17.

Sood R, Hansen N, Donovan F, Carrington B, Bucci D, Maskeri B . Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia. 2015; 30(2):501-4. PMC: 4679720. DOI: 10.1038/leu.2015.141. View

18.

Byrd J, Ruppert A, Mrozek K, Carroll A, Edwards C, Arthur D . Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004; 22(6):1087-94. DOI: 10.1200/JCO.2004.07.012. View

19.

Zhu H, Zhang X, Qin Y, Liu D, Jiang H, Chen H . MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013; 121(20):4056-62. DOI: 10.1182/blood-2012-11-468348. View

20.

Burnett A, Hills R, Milligan D, Kjeldsen L, Kell J, Russell N . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2010; 29(4):369-77. DOI: 10.1200/JCO.2010.31.4310. View